Introduction Since their introduction, drug-eluting stents (DES) have revolutionized percutaneous treatment of coronary artery disease with rates of in-stent restenosis of between 2 and 10% [] and ...

Boston Scientific BSX has announced plans to acquire carotid artery device specialist Silk ... in stent design and an aging global population. Key players are innovating with drug-eluting and ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

You’ll usually need to continue dual antiplatelet drug therapy for a year after a drug-eluting stent placement and a month after a bare-metal stent placement. Drug-eluting stents are a newer ...

More recently, drug-eluting stents (DESs) have emerged as the predominant percutaneous strategy in patients with coronary artery disease. This Review summarizes the knowledge on coronary stenting ...

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is ...

Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant b ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...

Boston Scientific has recently reported the results of the Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI)trial; part of the JACTAX stent program. [30] The JACTAX stent con ...